Literature DB >> 7537851

Endothelial interferon regulatory factor 1 cooperates with NF-kappa B as a transcriptional activator of vascular cell adhesion molecule 1.

A S Neish1, M A Read, D Thanos, R Pine, T Maniatis, T Collins.   

Abstract

Transcription of the vascular cell adhesion molecule 1 (VCAM-1) gene in endothelial cells is induced by lipopolysaccharide and the inflammatory cytokines interleukin-1 beta and tumor necrosis factor alpha (TNF-alpha). Previous studies have demonstrated that tandem binding sites for the inducible transcription factor NF-kappa B are necessary but not sufficient for full cytokine-mediated transcriptional activation. Herein, we demonstrate that full cytokine-induced accumulation of VCAM1 transcript requires protein synthesis. We report the definition of a functional regulatory element in the VCAM1 promoter interacting with the transcriptional activator interferon regulatory factor 1 (IRF-1). DNA-protein binding studies with endothelial nuclear extracts revealed that IRF-1 is cytokine inducible and binds specifically to a consensus sequence motif located 3' of the TATA element. We have identified heterodimeric p65 and p50 as the NF-kappa B species binding to the VCAM1 promoter in TNF-alpha-activated endothelial cells. Experiments with recombinant proteins showed that p50/p65 and high-mobility-group I(Y) protein cooperatively facilitated the binding of IRF-1 to the VCAM1 IRF binding site and that IRF-1 physically interacted with p50 and with high-mobility-group I(Y) protein. Transient transfection assay in endothelial cells showed that overexpressed IRF-1 resulted in superinduction of TNF-alpha-stimulated transcription. Site-directed mutations in the IRF binding element decreased TNF-alpha-induced activity and totally abolished superinduction. Cotransfection assays in P19 embryonal carcinoma cells revealed that IRF-1 synergized with p50/p65 NF-kappa B to activate the VCAM1 promoter or heterologous promoter constructs bearing isolated VCAM1 NF-kappa B and IRF binding motifs. Cytokine inducibility of VCAM1 in endothelial cells utilizes the interaction of heterodimeric p50/p65 proteins with IRF-1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537851      PMCID: PMC230486          DOI: 10.1128/MCB.15.5.2558

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  70 in total

1.  Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis.

Authors:  M I Cybulsky; M A Gimbrone
Journal:  Science       Date:  1991-02-15       Impact factor: 47.728

2.  The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function.

Authors:  D W Ballard; W H Walker; S Doerre; P Sista; J A Molitor; E P Dixon; N J Peffer; M Hannink; W C Greene
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

3.  Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues.

Authors:  G E Rice; J M Munro; C Corless; M P Bevilacqua
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

4.  Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.

Authors:  T Matsuyama; T Kimura; M Kitagawa; K Pfeffer; T Kawakami; N Watanabe; T M Kündig; R Amakawa; K Kishihara; A Wakeham
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

5.  Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation.

Authors:  G C Gurtner; V Davis; H Li; M J McCoy; A Sharpe; M I Cybulsky
Journal:  Genes Dev       Date:  1995-01-01       Impact factor: 11.361

6.  A striking similarity in the organization of the E-selectin and beta interferon gene promoters.

Authors:  M Z Whitley; D Thanos; M A Read; T Maniatis; T Collins
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

7.  Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha determine pools of constitutive and inducible NF-kappa B activity.

Authors:  P Dobrzanski; R P Ryseck; R Bravo
Journal:  EMBO J       Date:  1994-10-03       Impact factor: 11.598

8.  A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture.

Authors:  K Miyake; K Medina; K Ishihara; M Kimoto; R Auerbach; P W Kincade
Journal:  J Cell Biol       Date:  1991-08       Impact factor: 10.539

9.  Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules.

Authors:  B S Bochner; F W Luscinskas; M A Gimbrone; W Newman; S A Sterbinsky; C P Derse-Anthony; D Klunk; R P Schleimer
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

10.  Adhesion of human B cells to follicular dendritic cells involves both the lymphocyte function-associated antigen 1/intercellular adhesion molecule 1 and very late antigen 4/vascular cell adhesion molecule 1 pathways.

Authors:  G Koopman; H K Parmentier; H J Schuurman; W Newman; C J Meijer; S T Pals
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

View more
  70 in total

1.  Transcriptional activation by NF-kappaB requires multiple coactivators.

Authors:  K A Sheppard; D W Rose; Z K Haque; R Kurokawa; E McInerney; S Westin; D Thanos; M G Rosenfeld; C K Glass; T Collins
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1.

Authors:  D B Landry; L L Couper; S R Bryant; V Lindner
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation.

Authors:  J L Cheshire; A S Baldwin
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

4.  Replacement of the C-terminal tetrapeptide (314 PAPV 317 to 314 SSSM 317) in interferon regulatory factor-2 alters its N-terminal DNA-binding activity.

Authors:  Krishna Prakash; Pramod C Rath
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

5.  Multivalent DNA-binding properties of the HMG-1 proteins.

Authors:  J F Maher; D Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

6.  Inhibition of bovine endothelial cell activation in vitro by regulated expression of a transdominant inhibitor of NF-kappa B.

Authors:  J Anrather; V Csizmadia; C Brostjan; M P Soares; F H Bach; H Winkler
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

7.  Up-regulation of intestinal nuclear factor kappa B and intercellular adhesion molecule-1 following traumatic brain injury in rats.

Authors:  Chun-Hua Hang; Ji-Xin Shi; Jie-Shou Li; Wei-Qin Li; Hong-Xia Yin
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

8.  Heparin Attenuates the Expression of TNFalpha-induced Cerebral Endothelial Cell Adhesion Molecule.

Authors:  Jeong Ho Lee; Chul Hoon Kim; Gi Ho Seo; Jinu Lee; Joo Hee Kim; Dong Goo Kim; Young Soo Ahn
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

9.  Distamycin A inhibits HMGA1-binding to the P-selectin promoter and attenuates lung and liver inflammation during murine endotoxemia.

Authors:  Rebecca M Baron; Silvia Lopez-Guzman; Dario F Riascos; Alvaro A Macias; Matthew D Layne; Guiying Cheng; Cailin Harris; Su Wol Chung; Raymond Reeves; Ulrich H von Andrian; Mark A Perrella
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

10.  Ste20-related proline/alanine-rich kinase (SPAK) regulated transcriptionally by hyperosmolarity is involved in intestinal barrier function.

Authors:  Yutao Yan; Guillaume Dalmasso; Hang Thi Thu Nguyen; Tracy S Obertone; Shanthi V Sitaraman; Didier Merlin
Journal:  PLoS One       Date:  2009-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.